1. Pink Sheet
  3. >>North America
  4. >>United States

Lemtrada Advisory Committee’s Flexibility May Not Make FDA Bend

 
• By Sarah Karlin-Smith

Panel agrees with agency that Genzyme’s pivotal trials for MS drug don’t meet FDA approval standards, then casts conflicting votes supporting drug.

FDA’s Peripheral and Central Nervous System cast a potentially fatal vote Nov. 13, agreeing with the agency that Genzyme Corp./Sanofi’s pivotal trials for multiple sclerosis candidate Lemtrada (alemtuzumab) were not adequate and well-controlled – necessary qualifications for drug approval.

But the panel quickly followed that vote with a supportive vote on the drug’s efficacy and later a vote that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

US FDA’s Project CoGenT At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

BIO Notebook: PRVs Need To Be A Priority, IPO Window Shut And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement

 
• By Dean Rudge

Lupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster.

More from North America